Tag Archives: TAVR

By pass y actividad de la enfermedad en la arteria coronaria nativa

Clinical Impact of Coronary Artery Disease on Results After TAVR

Clinical Impact of Coronary Artery Disease on Results After TAVR

Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Percutaneous Access Closure in TAVR: Are Devices Similar?

One of the challenges that transcatheter aortic valve replacement (TAVR) continues to face is percutaneous access closure with percutaneous closure systems (PCS). However, several systems have been developed, either by plug—such as the MANTA system—or by suture (SU)—such as the ProStar and ProGlide systems. Both of these have been tested in different analyses, but to

La prudencia es buena consejera para decidir una transfusión en el TAVI

Prosthesis Mismatch in TAVR: It’s Real Impact

Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot. PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2  Research studies on surgical prosthesis have

Endocarditis infecciosa post TAVI

Amyloidosis and TAVR: Does this Disease Have an Impact?

Amyloidosis is a systemic disease that affects different organs and impairs their function. Recent studies with magnetic resonance imaging (MRI) have shown that between 13% and 16% of patients who undergo transcatheter aortic valve replacement (TAVR) have amyloidosis.  A review of four studies showed that mortality at 20 months was twice as high when amyloidosis

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

When Is It Best to Fracture a Bioprosthesis in TAVR?

At present, surgical aortic valve replacement (SAVR) uses bioprostheses. However, when these fail, we are presented with a great challenge, seeing as repeat SAVR involves a higher risk. In this context, valve-in-valve (V-in-V TAVR) has surged as a very attractive alternative.  Bioprosthesis fracture (BPF) is a new interesting strategy that has shown lower gradient and

Desafíos pendientes con el acceso radial

TAVR: Vascular Access in Patients with Peripheral Artery Disease, 1-Year Outcomes

At present, the transfemoral access (TFA) is the preferred approach when it comes to transcatheter aortic valve replacement (TAVR). However, 5 to10% of PAD patients present tortuous iliac anatomy and calcification, aortic aneurysms or prior peripheral intervention, which makes it impossible.  There are several alternatives to approach these patients: 1) TFA associated to peripheral PCI

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical risk. The current ACC and AHA guidelines recommend that a Heart Team make the decision for 65 to 80-year-old patients with aortic stenosis.  In low risk patients, fast recovery and short term benefits of TAVR should be weighed

Cambios fisiológicos y clínicos luego de reparar la tricúspide

Coronary Physiology after Aortic Valve Intervention

Impact of Aortic Valve Intervention on Coronary Flow Reserve Myocardial flow might be compromised in patients with severe aortic stenosis, which might be driven by CAD and concomitant atherosclerosis or a compromised capillary bed. Capillary circulation might be compromised by increased left ventricular mass (LVM) which in turn might alter coronary flow reserve (CFR).  Multiple

Manejo quirúrgico o percutáneo de los leaks mitrales

TAVR and New Onset LBBB

The safety and efficacy of transcatheter aortic valve replacement (TAVR) is already established. However, it still poses a challenge for conduction disturbances, such as the need for pacemaker or new onset left bundle branch block (LBBB). The current rate for the latter ranges from approximately 11% to 19%. In most cases, 50% of LBBB reverses

Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients with severe symptomatic aortic stenosis treated with aortic valve replacement might still present cardiac failure, even after successful procedures.   According to some reports, the incidence of cardiac failure after TAVR varies between 9% and 24%. The prognostic relevance of rehospitalization in these patients has not been studied yet; in fact, it remains unclear whether

Top